妊娠期百日咳免疫接种后的免疫原性、百日咳抗体的经胎盘转移及安全性:一项随机安慰剂对照试验的证据
这项IV期观察者盲法随机安慰剂对照多中心试验评估妊娠期接种减抗原成分破伤风-白喉-三组分无细胞百日咳疫苗(Tdap)的免疫原性、母体百日咳抗体经胎盘转移、反应原性和安全性。687名孕妇在妊娠27-36周接种Tdap或安慰剂,结果显示脐带血百日咳抗体几何平均浓度比值(Tdap/对照)均优于1.5,母婴相关不良事件两组相似,未报告与母体Tdap接种相关的严重不良事件。
要点
- 妊娠期接种Tdap后脐带血百日咳抗体几何平均浓度比值(Tdap/对照)为8.5至20.7。
- 妊娠/新生儿相关不良事件、征集性全身不良事件和非征集性不良事件两组相似。
- 研究期间报告的严重不良事件均未被认为与母体Tdap接种相关。
核心结论
- 妊娠期接种Tdap可在脐带血中产生高水平百日咳抗体,耐受性良好且安全性可接受,支持妊娠期接种Tdap以预防早期婴儿百日咳病的推荐。
研究设计与样本
- 这是一项IV期、观察者盲法、随机、安慰剂对照、多中心试验,评估妊娠期接种减抗原成分破伤风-白喉-三组分无细胞百日咳疫苗(Tdap)的免疫原性、母体百日咳抗体经胎盘转移、反应原性和安全性。
- 687名孕妇在妊娠27-36周接种Tdap或安慰剂,并在产后≤72小时内交叉接种;Tdap组N=341,对照组N=346。
- 免疫应答在妊娠期接种前、接种后1个月以及分娩时脐带血中评估。
- 主要目标为优效性:若脐带血中百日咳几何平均浓度(GMC)比值(Tdap/对照)的95%置信区间(CI)下限≥1.5,则达到优效性。
- 记录征集性和非征集性不良事件(AEs)以及妊娠/新生儿相关关注的不良事件。
主要发现
- 脐带血中母体转移的百日咳抗体GMC比值(Tdap/对照)为:抗丝状血凝素16.1(95% CI:13.5-19.2),抗百日咳杆菌黏附素20.7(15.9-26.9),抗百日咳类毒素8.5(7.0-10.2)。
- 妊娠/新生儿相关关注的不良事件、征集性全身不良事件和非征集性不良事件的发生率两组相似。
- 研究期间报告的所有严重不良事件均未被认为与母体Tdap接种相关。
关键数值与推荐
- 优效性标准:脐带血百日咳GMC比值(Tdap/对照)的95% CI下限≥1.5。
- 抗丝状血凝素GMC比值(Tdap/对照)16.1(95% CI:13.5-19.2)。
- 抗百日咳杆菌黏附素GMC比值(Tdap/对照)20.7(95% CI:15.9-26.9)。
- 抗百日咳类毒素GMC比值(Tdap/对照)8.5(95% CI:7.0-10.2)。
临床怎么用
- 作者结论指出,妊娠期接种Tdap可在脐带血中产生高水平百日咳抗体,耐受性良好且安全性可接受。
- 作者认为该结果支持妊娠期接种Tdap以预防早期婴儿百日咳病的推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pertussis immunization during pregnancy is recommended in many countries. Data from large randomized controlled trials are needed to assess the immunogenicity, reactogenicity and safety of this approach. METHODS: This phase IV, observer-blind, randomized, placebo-controlled, multicenter trial assessed immunogenicity, transplacental transfer of maternal pertussis antibodies, reactogenicity and safety of a reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap) during pregnancy. Women received Tdap or placebo at 27-36 weeks' gestation with crossover ≤ 72-hour-postpartum immunization. Immune responses were assessed before the pregnancy dose and 1 month after, and from the umbilical cord at delivery. Superiority (primary objective) was reached if the lower limits of the 95% confidence intervals (CIs) of the pertussis geometric mean concentration (GMC) ratios (Tdap/control) in cord blood were ≥ 1.5. Solicited and unsolicited adverse events (AEs) and pregnancy-/neonate-related AEs of interest were recorded. RESULTS: 687 pregnant women were vaccinated (Tdap: N = 341 control: N = 346). Superiority of the pertussis immune response (maternally transferred pertussis antibodies in cord blood) was demonstrated by the GMC ratios (Tdap/control): 16.1 (95% CI: 13.5-19.2) for anti-filamentous hemagglutinin, 20.7 (15.9-26.9) for anti-pertactin and 8.5 (7.0-10.2) for anti-pertussis toxoid. Rates of pregnancy-/neonate-related AEs of interest, solicited general and unsolicited AEs were similar between groups. None of the serious AEs reported throughout the study were considered related to maternal Tdap vaccination. CONCLUSIONS: Tdap vaccination during pregnancy resulted in high levels of pertussis antibodies in cord blood, was well tolerated and had an acceptable safety profile. This supports the recommendation of Tdap vaccination during pregnancy to prevent early-infant pertussis disease. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02377349.
引用
- Perrett KP, Halperin SA, Nolan T, et al. Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. Vaccine. 2019. PMID: 31776029. doi:10.1016/j.vaccine.2019.10.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。